Skip to main
RYTM
RYTM logo

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals (RYTM) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rhythm Pharmaceuticals Inc. has a positive outlook due to strong revenue performance, recording $41.8 million in top-line revenue for 4Q24, significantly surpassing forecasts of $35.9 million. The anticipation of positive Phase 3 trial results for its MC4R agonist, IMCIVREE, particularly in the treatment of hypothalamic obesity, is expected to enhance peak sales potential further. Additionally, the company's stock has demonstrated resilience and strong performance relative to the S&P 500 and XBI indices, reaching a two-year high of $67 in early November 2024, bolstered by successful product launches and impressive clinical data.

Bears say

Rhythm Pharmaceuticals has accumulated substantial losses and is not expected to achieve profitability for several years, raising concerns about its financial sustainability. Key risks include the potential failure to produce favorable data from clinical trials, challenges in obtaining regulatory approvals for setmelanotide in additional indications, and setbacks related to earlier-stage candidates, all of which could hinder commercial success. Furthermore, a lower-than-anticipated number of treatable patients for related diseases and a slow sales ramp for IMCIVREE may materially impact revenue projections, contributing to a negative outlook for the company's stock.

Rhythm Pharmaceuticals (RYTM) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rhythm Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rhythm Pharmaceuticals (RYTM) Forecast

Analysts have given Rhythm Pharmaceuticals (RYTM) a Strong Buy based on their latest research and market trends.

According to 15 analysts, Rhythm Pharmaceuticals (RYTM) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rhythm Pharmaceuticals (RYTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.